Trial reportNature communications2026
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03464942 (A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer
Who cites it
2 citing papers in PubMed.
- Review
- Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-clinical evidence suggests that stereotactic ablative body radiotherapy (SABR) can enhance systemic anti-tumor responses when combined with immune checkpoint inhibition, although optimal fractionation remains uncertain. Here we conducted a phase II multi-center randomized trial (AZTEC trial; ClinicalTrials.gov identifier NCT03464942) to investigate the efficacy and safety of single-fraction (SF: 20 Gy; n = 27) or multi-fraction (MF: 24 Gy in three fractions; n = 27) SABR followed by anti-PD-L1 atezolizumab in 54 women with advanced triple-negative breast cancer (TNBC) as first or second-line treatment. The primary endpoint was progression free survival (PFS). Secondary endpoints included best overall response rate, clinical benefit rate, overall survival and safety. We observed that both treatment arms had similar efficacy: median PFS was 2.5 months (90% CI: 1.7-4.5) for SF and 3.1 months (90% CI: 1.8-3.9) for MF. The null hypothesis (PFS of 2 months) was not rejected in either arm. Clinical benefit (RECIST complete response/partial response or stable disease for ≥24 weeks) was achieved in 5 (20%) SF and 6 (25%) MF patients, all with oligometastatic disease, independent of PD-L1 expression. Adverse events were similar between arms. Prespecified exploratory analysis of peripheral blood found higher CD8 T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.